Osteoarthritis News and Research

Latest Osteoarthritis News and Research

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

FDA selects Rochester to lead initiative to identify improved pain treatments

Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.

2 Nov 2010

Physicians suggest patients who receive MoM hip replacement to pay attention on post-operative pain

Total hip arthroplasty (THA) is one of the most successful surgeries of the past several decades. This procedure has relieved pain and restored movement to hundreds of thousands of people. The decision to have hip replacement surgery should be only made after discussion between the patient and his or her orthopaedic surgeon.

30 Oct 2010

VIVUS receives FDA CRL for QNEXA NDA

VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

29 Oct 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Metagenics, Inc. has been awarded two new patents for discoveries relating to its research on the anti-inflammatory properties of reduced iso-alpha acids (RIAA) derived from hops. Metagenics is a life sciences company focused on reversing chronic illness and improving health through therapeutic nutrition and lifestyle changes. The discoveries were made by researchers at Metagenics’ wholly-owned biotechnology subsidiary, MetaProteomics® LLC.

28 Oct 2010

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2010.

28 Oct 2010

Artimplant reports net loss of SEK 5.2 million for 2010 third quarter

Artimplant AB: Net revenue for the third quarter amounted to SEK 5.1 million (5.5) and for January-September SEK 14.9 million (18.2).

28 Oct 2010

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Emisphere Technologies, Inc. announced today that Novartis Pharma AG provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Bioscience with oral calcitonin (SMC021).

25 Oct 2010

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.

22 Oct 2010

Lubricin reduces wear to bone cartilage

A team of researchers in North Carolina has discovered that lubricin, a synovial fluid glycoprotein, reduces wear to bone cartilage. This result, which has implications for the treatment of sufferers of osteoarthritis, will be presented today at the AVS 57th International Symposium & Exhibition, taking place this week at the Albuquerque Convention Center in New Mexico.

21 Oct 2010

U.S. Bone and Joint Decade observes National Action Week

An annual global event, Bone and Joint National Action Week is held October 12-20 with activities focused on disorders including arthritis, back pain, osteoporosis, and the effects of childhood obesity on the musculoskeletal system. Events and projects organized worldwide are designed to raise awareness of prevention, disease management and treatments. In the United States, the U.S. Bone and Joint Decade represents the global initiative.

14 Oct 2010

Arthritis Foundation launches new initiatives on World Arthritis Day

The already staggering social and economic impact of arthritis in the United States is set to explode during the coming decades, says the Arthritis Foundation in response to a Centers for Disease Control and Prevention (CDC) report published in the Oct. 8 issue of Morbidity and Mortality Weekly Report, which coincides with World Arthritis Day on Tuesday, Oct. 12.

8 Oct 2010

Integra Total Wrist Fusion System to be featured at ASSH Annual Meeting

Integra LifeSciences Holdings Corporation announced today that it is featuring the Integra Total Wrist Fusion System at the 65th Annual Meeting of the American Society for Surgery of the Hand (ASSH) on October 7-9, in Boston, Massachusetts.

7 Oct 2010

ATR product improves clinical outcome in patients with soft tissue defects in foot

Reported cases, by Dr. Jan Lidström, which involve 20 patients with soft tissue defects in the foot with up to four years follow-up together with a biomechanical study, by Dr. Eric Giza, confirm the positive clinical outcome orthopedic foot surgeons have experienced with Artelon Tissue Reinforcement (ATR).

6 Oct 2010

CrystalGenomics to present Phase I MAD study data at Arrowhead Summit

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc. a drug discovery and development biopharmaceutical company, has announced that Dr. William Schmidt, its Vice President of Clinical Development, has been invited to present a talk on Development of CG100649, Tissue-selective Dual Inhibitor of COX-2 and Carbonic Anhydrase for Treatment of Osteoarthritis at Arrowhead's upcoming 4th Annual Pain Therapeutics Summit, to be held on October 4-5, 2010 in Philadelphia.

5 Oct 2010

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets.

4 Oct 2010

Study shows Artelon scaffold improves cartilage repair outcome

A laboratory study (in vitro) and an animal study, which are currently being presented at the 9th World Congress of the International Cartilage Repair Society, demonstrate that Artelon functions as a scaffold for cells in conjunction with cartilage repair.

29 Sep 2010

Study confirms Artelon Cosmetic can treat patients with tissue defects

A post-market study has been conducted by the Brånemark Clinic in Gothenburg on Artelon Cosmetic for soft tissue augmentation in the upper jaw. The study confirms that patients with tissue defects can be treated successfully with Artelon Cosmetic.

28 Sep 2010

Calcitonin combination therapy may help treat osteoarthritis: Study

Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis.

27 Sep 2010

Interleukin Genetics announces clinical study data on osteoarthritis progression

Interleukin Genetics, Inc. and the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill announced today findings from a large clinical study to evaluate the role of genetic factors in osteoarthritis progression which showed patients with radiographic evidence of knee osteoarthritis who inherited a specific pattern of genetic variations in the interleukin-1 receptor antagonist (IL-1Ra) gene were almost twice as likely to progress to severe disease as other patients.

23 Sep 2010

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

FDA selects Rochester to lead initiative to identify improved pain treatments

Physicians suggest patients who receive MoM hip replacement to pay attention on post-operative pain

VIVUS receives FDA CRL for QNEXA NDA

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

Artimplant reports net loss of SEK 5.2 million for 2010 third quarter

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Lubricin reduces wear to bone cartilage

U.S. Bone and Joint Decade observes National Action Week

Arthritis Foundation launches new initiatives on World Arthritis Day

Integra Total Wrist Fusion System to be featured at ASSH Annual Meeting

ATR product improves clinical outcome in patients with soft tissue defects in foot

CrystalGenomics to present Phase I MAD study data at Arrowhead Summit

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

Study shows Artelon scaffold improves cartilage repair outcome

Study confirms Artelon Cosmetic can treat patients with tissue defects

Calcitonin combination therapy may help treat osteoarthritis: Study

Interleukin Genetics announces clinical study data on osteoarthritis progression

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in